Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
You may also be interested in...
Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel
Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.
CSL Behring's Hemophilia B Drug May Have Dosing Advantage
FDA clears Idelvion, a long-acting recombinant albumin fusion protein, with potential to provide up to 14-day dosing; Biogen's Alprolix is dosed once weekly.
Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen
Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.